POLYCYTHEMIA VERA (PV)
Clinical trials for POLYCYTHEMIA VERA (PV) explained in plain language.
Never miss a new study
Get alerted when new POLYCYTHEMIA VERA (PV) trials appear
Sign up with your email to follow new studies for POLYCYTHEMIA VERA (PV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a targeted drug outperform standard care for rare blood cancers?
Disease control OngoingThis trial compares the drug ruxolitinib against the best available standard treatments for people with high-risk polycythemia vera (PV) or essential thrombocythemia (ET), two rare blood cancers that cause overproduction of blood cells and can lead to clots, bleeding, and severe …
Matched conditions: POLYCYTHEMIA VERA (PV)
Phase: PHASE2 • Sponsor: RWTH Aachen University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug aims to reduce Blood-Letting in rare blood cancer
Disease control OngoingThis study tests an experimental drug called DISC-3405 in 60 adults with polycythemia vera, a condition where the body makes too many red blood cells. The goal is to see if the drug can safely lower the need for phlebotomies (blood removal) and control blood counts. Participants …
Matched conditions: POLYCYTHEMIA VERA (PV)
Phase: PHASE2 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC